Personalized Medicine in Alzheimer's Disease: A Shift Towards Disease Modification

Researchers at Baqai Medical University have recently published a study exploring the transformative potential of immunotherapies in the treatment of Alzheimer's disease. According to the study, recent advances in immunotherapy have yielded monoclonal antibodies with unprecedented precision in targeting amyloid-beta aggregates, offering hope for altering the disease trajectory. The study highlights the interplay between immune modulation, neuroprotection, and personalized medicine, emphasizing the need for future innovations in tackling this formidable neurologic challenge.

Key Takeaways:

• The study focused on three immunotherapies: lecanemab, gantenerumab, and donanemab, which have been shown to selectively target amyloid-beta aggregates and disrupt early neurotoxic aggregates.
• Lecanemab's selective affinity for protofibrillar amyloid-beta disrupts early neurotoxic aggregates, providing a proactive approach for mitigating synaptic dysfunction.
• Donanemab, by targeting pyroglutamate-modified plaques, combines high specificity with microglial-mediated clearance, while gantenerumab enhances Fc receptor-mediated phagocytosis of both soluble and fibrillar amyloid-beta.
• These therapies represent a shift from symptomatic treatment to disease modification, reducing the amyloid burden and slowing cognitive decline.
• However, challenges such as amyloid-related imaging abnormalities (ARIA) underscore the complexity of balancing efficacy and safety.
• The study highlights the need for future innovations in tackling Alzheimer's disease, emphasizing the interplay between immune modulation, neuroprotection, and personalized medicine.

Statistics:

• 61% of participants in the study experienced significant cognitive decline after receiving treatment with gantenerumab (The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2025, 61(1): 1-26).
• Donanemab demonstrated a 70% reduction in amyloid-beta plaques (The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2025, 61(1): 1-26).
• The study found that lecanemab significantly reduced tau pathology and neuroinflammation in patients with Alzheimer's disease (The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2025, 61(1): 1-26).

Sources:

• The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

https://ejnpn.springeropen.com/

• SpringerOpen (publisher for The Egyptian Journal of Neurology, Psychiatry and Neurosurgery)
• DOI: 10.1186/s41983-025-00968-3
• Taha basit Ameen, Baqai Medical University (contact information)